Post-COVID syndrome symptoms, functional disability, and clinical severity phenotypes in hospitalized and nonhospitalized individuals: A cross-sectional evaluation from a community COVID rehabilitation service.
C19-YRS
SARS CoV-2
long COVID
phenotypes
post-COVID-19 condition
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
31
10
2021
accepted:
14
11
2021
pubmed:
17
11
2021
medline:
5
3
2022
entrez:
16
11
2021
Statut:
ppublish
Résumé
There is currently limited information on clinical severity phenotypes of symptoms and functional disability in post-coronavirus disease 2019 (COVID) Syndrome (PCS). A purposive sample of 370 PCS patients from a dedicated community COVID-19 rehabilitation service was assessed using the COVID-19 Yorkshire Rehabilitation Scale where each symptom or functional difficulty was scored on a 0-10 Likert scale and also compared with before infection. Phenotypes based on symptom severity were extracted to identify any noticeable patterns. The correlation between symptom severity, functional disability, and overall health was explored. The mean age was 47 years, with 237 (64%) females. The median duration of symptoms was 211 days (interquartile range 143-353). Symptoms and functional difficulties increased substantially when compared to before infection. Three distinct severity phenotypes of mild (n = 90), moderate (n = 186), and severe (n = 94) were identified where the severity of individual symptoms was of similar severity within each phenotype. Symptom scores were strongly positively correlated with functional difficulty scores (0.7, 0.6-0.7) and moderately negatively correlated with overall health (-0.4, -0.3, to -0.5). This is the first study reporting on severity phenotypes in a largely nonhospitalized PCS cohort. Severity phenotypes might help stratify patients for targeted interventions and planning of care pathways.
Identifiants
pubmed: 34783052
doi: 10.1002/jmv.27456
pmc: PMC8661751
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1419-1427Subventions
Organisme : National Institute for Health Research
Organisme : Medical Research Council
Pays : United Kingdom
Informations de copyright
© 2021 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
Références
EClinicalMedicine. 2021 Aug;38:101019
pubmed: 34308300
J Med Virol. 2021 Dec;93(12):6566-6574
pubmed: 34255355
J Med Virol. 2022 Mar;94(3):1027-1034
pubmed: 34676578
BMJ. 2021 Apr 1;373:n853
pubmed: 33795224
BMJ. 2020 Dec 23;371:m4938
pubmed: 33361141
J Prim Care Community Health. 2021 Jan-Dec;12:21501327211010994
pubmed: 33880955
Clin Med (Lond). 2021 Jan;21(1):e63-e67
pubmed: 33243837
Pain Res Manag. 2020 May 8;2020:2741278
pubmed: 32454919
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
Nat Immunol. 2022 Feb;23(2):210-216
pubmed: 35027728
Brain Behav Immun. 2022 Jul;103:154-162
pubmed: 35447302
J Med Virol. 2022 Apr;94(4):1419-1427
pubmed: 34783052
J Rehabil Med. 2020 Aug 24;52(8):jrm00089
pubmed: 32830284
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Lancet Respir Med. 2021 Nov;9(11):1275-1287
pubmed: 34627560